At close: December 13 at 4:00:01 PM EST
After hours: 7:59:22 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Carole S. Ben-Maimon M.D. | CEO, President & Director | 865k | -- | 1959 |
| Mr. Michael Celano CPA | Secretary & CFO | 577.58k | -- | 1959 |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer | 593.02k | -- | 1971 |
| Mr. John Berman | Vice President of Finance & Administration | -- | -- | -- |
| Ms. Jennifer Spokes Johansson | Vice President of Legal & Compliance | -- | -- | -- |
| Dr. Russell G. Clayton Sr., D.O, D.O. | Chief Medical Officer | -- | -- | 1961 |
| Mr. Francis Michael Conway CPA | VP & Controller | -- | -- | -- |
Larimar Therapeutics, Inc.
Three Bala Plaza East
Suite 506
Bala Cynwyd, PA 19004
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 42
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Corporate Governance
Larimar Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 12, 2025 at 10:59 AM UTC - March 17, 2025 at 12:00 PM UTC
Larimar Therapeutics, Inc. Earnings Date
Recent Events
May 22, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
Related Tickers
CRVS Corvus Pharmaceuticals, Inc.
7.38
-8.66%
INZY Inozyme Pharma, Inc.
3.0300
+1.68%
SLRN Acelyrin, Inc.
3.2300
-8.76%
STOK Stoke Therapeutics, Inc.
12.06
-2.11%
ATYR aTyr Pharma, Inc.
3.0600
+1.32%
SPRB Spruce Biosciences, Inc.
0.3832
-1.01%
DAWN Day One Biopharmaceuticals, Inc.
12.75
-0.47%
ANAB AnaptysBio, Inc.
15.59
+3.79%
EWTX Edgewise Therapeutics, Inc.
27.62
-1.88%
BCYC Bicycle Therapeutics plc
13.81
-31.33%